Increased expression of the NOD-like receptor family, pyrin domain containing 3 inflammasome in dermatomyositis and polymyositis is a potential contributor to their pathogenesis

Chinese Medical Journal

Volumn 129, Issue 9, 2016, Pages 1047-1052

  Yin, Xi ^a   Han, Gen Cheng ^b   Jiang, Xing Wei ^b   Shi, Qiang ^a   Pu, Chuan Qiang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Autoimmunity; Dermatomyositis; NOD like receptor family; Polymyositis; Pyrin domain containing 3 inflammasome

Indexed keywords

CREATINE KINASE; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LACTATE DEHYDROGENASE; MESSENGER RNA; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROTEIN P20; NLRP3 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE DURATION; ELECTROMYOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; INTRACELLULAR SIGNALING; MALE; MUSCLE WEAKNESS; PATHOGENESIS; POLYMYOSITIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; GENETICS; MIDDLE AGED; PHYSIOLOGY;

ADULT; CASPASE 1; DERMATOMYOSITIS; FEMALE; HUMANS; INFLAMMASOMES; INTERLEUKIN-18; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; POLYMYOSITIS;

EID: 84963732685     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.4103/0366-6999.180528     Document Type: Article

References (30)

1. Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015; 372: 1734-47. doi: 10.1056/NEJMra1402225.
2. De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2009;21:610-6. doi: 10.1097/BOR.0b013e3283317b31.
3. Ernste FC, Reed AM. Idiopathic inflammatory myopathies: Current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 2013;88:83-105. doi: 10.1016/j.mayocp.2012.10.017.
4. Luo YB, Mastaglia FL. Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta 2015;1852:622-32. doi: 10.1016/j.bbadis.2014.05.034.
5. Pestronk A. Acquired immune and inflammatory myopathies: Pathologic classification. Curr Opin Rheumatol 2011;23:595-604. doi: 10.1097/BOR.0b013e32834bab42.
6. Martinon F, Burns K, Tschopp J. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-26. doi: 10.1016/S1097-2765(02)00599-3.
7. Elliott EI, Sutterwala FS. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol Rev 2015;265:35-52. doi: 10.1111/imr.12286.
8. Rathinam VA, Vanaja SK, Waggoner L, Sokolovska A, Becker C, Stuart LM, et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell 2012;150:606-19. doi: 10.1016/j.cell.2012.07.007.
9. Mariathasan S, Weiss DS, Newton K, McBride J, O’Rourke K, Roose-Girma M, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006;440:228-32. doi: 10.1038/nature04515.
10. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41. doi: 10.1038/nature04516.
11. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008;9:857-65. doi: 10.1038/ni.1636.
12. Schroder K, Tschopp J. The inflammasomes. Cell 2010;140:821-32. doi: 10.1016/j.cell.2010.01.040.
13. Ozaki E, Campbell M, Doyle SL. Targeting the NLRP3 inflammasome in chronic inflammatory diseases: Current perspectives. J Inflamm Res 2015;8:15-27. doi: 10.2147/JIR.S51250.
14. Lundberg I, Kratz AK, Alexanderson H, Patarroyo M. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000;43:336-48. doi: 10.1002/1529-0131(200002)43:2<336:AID-ANR13>3.0.CO;2-V.
15. Tucci M, Quatraro C, Dammacco F, Silvestris F. Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp Immunol 2006;146:21-31. doi: 10.1111/j.1365-2249.2006.03180.x.
16. Yang X, Jiang X, Chen G, Xiao Y, Geng S, Kang C, et al. T cell Ig mucin-3 promotes homeostasis of sepsis by negatively regulating the TLR response. J Immunol 2013;190:2068-79. doi: 10.4049/jimmunol.1202661.
17. Dalakas MC. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev 2012;11:203-6. doi: 10.1016/j.autrev.2011.05.013.
18. Dalakas MC. Mechanisms of disease: Signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol 2006;2:219-27. doi: 10.1038/ncprheum0140.
19. Loell I, Lundberg IE. Can muscle regeneration fail in chronic inflammation: A weakness in inflammatory myopathies? J Intern Med 2011;269:243-57. doi: 10.1111/j.1365-2796.2010.02334.x.
20. Moran EM, Mastaglia FL. Cytokines in immune-mediated inflammatory myopathies: Cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol 2014;178:405-15. doi: 10.1111/cei.12445.
21. Schmidt J, Barthel K, Wrede A, Salajegheh M, Bähr M, Dalakas MC. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008;131(Pt 5):1228-40. doi: 10.1093/brain/awn053.
22. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-78. doi: 10.1002/ana.20464.
23. Baird GS, Montine TJ. Multiplex immunoassay analysis of cytokines in idiopathic inflammatory myopathy. Arch Pathol Lab Med 2008;132:232-8. doi: 10.1043/1543-2165(2008)132[232:MIAOCI] 2.0.CO;2.
24. Tucci M, Quatraro C, Dammacco F, Silvestris F. Increased IL-18 production by dendritic cells in active inflammatory myopathies. Ann N Y Acad Sci 2007;1107:184-92. doi: 10.1196/annals.1381.020.
25. Martinon F, Mayor A, Tschopp J. The inflammasomes: Guardians of the body. Annu Rev Immunol 2009;27:229-65. doi: 10.1146/annurev.immunol.021908.132715.
26. Cassel SL, Sutterwala FS. Sterile inflammatory responses mediated by the NLRP3 inflammasome. Eur J Immunol 2010;40:607-11. doi: 10.1002/eji.200940207.
27. Zong M, Bruton JD, Grundtman C, Yang H, Li JH, Alexanderson H, et al. TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann Rheum Dis 2013;72:1390-9. doi: 10.1136/annrheumdis-2012-202207.
28. Cseri K, Vincze J, Cseri J, Fodor J, Csernátony Z, Csernoch L, et al. HMGB1 expression and muscle regeneration in idiopathic inflammatory myopathies and degenerative joint diseases. J Muscle Res Cell Motil 2015;36:255-62. doi: 10.1007/s10974-015-9411-7.
29. Jin C, Flavell RA. Molecular mechanism of NLRP3 inflammasome activation. J Clin Immunol 2010;30:628-31. doi: 10.1007/s10875-010-9440-3.
30. Feng Y, Ni L, Wang Q. Administration of cathepsin B inhibitor CA-074Me reduces inflammation and apoptosis in polymyositis. J Dermatol Sci 2013;72:158-67. doi: 10.1016/j.jdermsci.2013.06.014.